Prolonged somatostatin pretreatment desensitizes somatostatin's inhibition of receptor-mediated release of adrenocorticotropin hormone and sensitizes adenylate cyclase

Endocrinology. 1983 Aug;113(2):811-3. doi: 10.1210/endo-113-2-811.


Addition of somatostatin-14 (SRIF) inhibits corticotropin releasing factor (CRF) and forskolin-stimulated cyclic AMP formation and ACTH release from tumor cells of the mouse anterior pituitary (AtT-20/D16-16). After long-term pretreatment of these cells with SRIF, the ability of SRIF to inhibit CRF and forskolin-stimulated cyclic AMP accumulation or ACTH secretion is markedly reduced. SRIF pretreatment also increases the formation of cyclic AMP in response to forskolin. This increase is delayed in onset, slow to recover, and blocked by the protein synthesis inhibitor, cycloheximide. SRIF pretreatment did not affect basal cyclic AMP and cyclic GMP levels or phosphodiesterase activity. It is proposed that prolonged treatment of AtT-20 cells with SRIF desensitizes SRIF receptors and induces a compensatory sensitization of adenylate cyclase through a process requiring protein synthesis.

MeSH terms

  • Adenylyl Cyclases / metabolism*
  • Adrenocorticotropic Hormone / metabolism*
  • Animals
  • Cell Line
  • Colforsin
  • Corticotropin-Releasing Hormone / pharmacology
  • Cyclic AMP / metabolism
  • Diterpenes / pharmacology
  • Mice
  • Pituitary Gland, Anterior / physiopathology
  • Pituitary Neoplasms / physiopathology*
  • Somatostatin / pharmacology*


  • Diterpenes
  • Colforsin
  • Somatostatin
  • Adrenocorticotropic Hormone
  • Corticotropin-Releasing Hormone
  • Cyclic AMP
  • Adenylyl Cyclases